Answers are grounded in this paper and cite their sources.
Since its approval in 1997 by the FDA, rituximab has been approved for use in certain B-cell lymphomas and treatment-resistant rheumatoid arthritis. Over the past 10 years, many case reports have indicated rituximab's efficacy in a number of inflammatory conditions in dermatology. This article includes a review of the mechanism of action, dosing, and side effect profile, as well as a review of the current literature on off-label uses of the CD20(+) B-cell antagonist rituximab.
No takes yet. Share an insight, caveat, or question.
Carr et al. (2007) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: